A phase I interventional clinical trial (NCT02349724) is currently evaluating the safety and efficacy of CEA-targeting CAR-T cells (CEA-TCB) in combination with atezolizumab, an anti-PD-L1 antibody, in patients with advanced CEA-positive solid tumors, including esophageal cancer and gastric cancer. Here, CEACAM5 is linked to esophageal cancer.